The first project briefed to KISS was the launch of NITYR™ (nitisinone) tablets a drug to treat patients with an ultra-rare disease called Hereditary Tyrosinaemia type 1 (HT-1), in the U.S. market. As Sarah Reakes, Managing Director of KISS, comments, the project required an entirely integrated approach.
“In launching NITYR we created a brand language and a full suite of specialised marketing collateral from brochures and presentations to a mobile responsive website in a matter of weeks. We also worked closely with our PROI partner agency, rbb Communications, in the U.S to develop the Americanised copy required for all these elements, as well as a launch to U.S. media."
“We are delighted to have been appointed by Cycle, a company working on some incredible innovations and a strong pipeline within the pharmaceutical industry.”
Paula Bekinschtein, Global Marketing Manager at Cycle Pharmaceuticals says: “This project was delivered in full in just six weeks, which is testament to the talented pool of professionals and the multi-disciplinary skill set within KISS. It was a big ask and their rapid response was exceptional without any compromise on the quality of their work - which is exactly what is needed within such a specialised healthcare sector as ours.”
For full prescribing information please visit: www.nityr.us/PI